Gadicke Ansbert's Form 4 filing
Entrada Therapeutics, Inc. (TRDA) · filed Dec 12, 2024
- Accession no.
- 0001415889-24-029141
- Filed
- Dec 12, 2024, 5:00 PM ET
- Trade date
- Dec 10-11, 2024
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions and 0 derivative transactions. Open-market sales total $917.1K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Gadicke AnsbertCIK 0001134655 | 10% Owner |
| Evnin LukeCIK 0001134657 | 10% Owner |
| Foley ToddCIK 0001473930 | 10% Owner |
| MPM BioVentures 2014, L.P.CIK 0001609492 | 10% Owner |
| MPM BioVentures 2014 (B), L.P.CIK 0001609493 | 10% Owner |
| MPM Asset Management Investors BV2014 LLCCIK 0001609495 | 10% Owner |
| MPM Bioventures 2018 (B), L.P.CIK 0001729504 | 10% Owner |
| MPM Asset Management Investors BV2018 LLCCIK 0001734817 | 10% Owner |
| MPM BioVentures 2014 LLCCIK 0001765021 | 10% Owner |
| MPM BioVentures 2014 GP LLCCIK 0001765091 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Dec 10, 2024 | Common Stock | SSaleDisposed | −22,935 | $20.77 | −$476,359.95 | 4,402,849 | Indirect | |
| Dec 11, 2024 | Common Stock | SSaleDisposed | −21,787 | $20.23 | −$440,751.01 | 4,381,062 | Indirect |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.